candesartan has been researched along with Abdominal Migraine in 17 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe the use of the antihypertensive, candesartan, with hydrochlorothiazide (ECARD Combination Tablets LD) as a preventive therapy that decreased the frequency of migraine accompanied by premonitory leg edema." | 3.79 | Migraine treated using a prophylactic combination of candesartan and hydrochlorothiazide (ECARD Combination Tablets LD). ( Akiyama, H; Hasegawa, Y, 2013) |
| " Rates of adverse events were similar for patients using and not using preventive medications." | 2.90 | Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. ( Ailani, J; Baygani, S; Hundemer, HP; Krege, JH; Loo, LS; Port, M; Schim, J, 2019) |
| "Candesartan was non-inferior to propranolol (and vice versa)." | 2.79 | A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. ( Aamodt, AH; Gravdahl, GB; Hagen, K; Linde, M; Sand, T; Stovner, LJ; Tronvik, E, 2014) |
| "The treatment of migraine depends on the frequency, severity and concomitant diseases." | 2.52 | [Role of antihypertensive drugs in the treatment of migraine]. ( Fehér, G; Pusch, G, 2015) |
| "Mild migraine attack can be treated with acetaminophen or NSAIDs either alone or combined with metoclopramide." | 2.52 | [Update on Current Care Guideline: Migraine]. ( , 2015) |
| "Lamotrigine is ineffective for migraine prevention (Level A)." | 2.48 | Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. ( Argoff, C; Ashman, E; Dodick, DW; Freitag, F; Holland, S; Silberstein, SD, 2012) |
| "ACE inhibitors and ARBs have migraine prophylaxis activity similar to that of some currently utilized agents." | 2.46 | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. ( Bailey, EK; Gales, BJ; Gales, MA; Reed, AN, 2010) |
| "Eighty-four patients (70%) had chronic migraine and 53 (42." | 1.62 | Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study. ( García-Azorín, D; Guerrero, ÁL; Martínez-Pías, E; Planchuelo-Gómez, Á; Sánchez-Rodríguez, C; Sierra, Á, 2021) |
| "Eighty-one patients (chronic migraine, n = 68) were included in the final analysis." | 1.56 | Candesartan in migraine prevention: results from a retrospective real-world study. ( Filippi, M; Goadsby, PJ; Lastarria Perez, CP; Messina, R, 2020) |
| "A pregnant young woman with a severe migraine is prescribed candesartan, an angiotensin II type 1 receptor antagonist (AT II antagonists)." | 1.36 | Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome. ( Haaland, K, 2010) |
| "347 migraine patients aged 18-68 (155 migraine without aura (MoA), 187 migraine with aura (MwA) and 5 missing aura subgroup data) and 403 healthy non-migrainous controls > 40 years of age were included in the study." | 1.35 | Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. ( Bovim, G; Gladwin, AJ; Owen, K; Schrader, H; Stovner, LJ; Tronvik, E; White, LR, 2008) |
| "Thus candesartan is considered to be a unique, attractive choice of prophylactic agent for migraine complicated by hypertension." | 1.32 | Efficacy of candesartan in the treatment of migraine in hypertensive patients. ( Owada, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Messina, R | 1 |
| Lastarria Perez, CP | 1 |
| Filippi, M | 1 |
| Goadsby, PJ | 1 |
| Sánchez-Rodríguez, C | 1 |
| Sierra, Á | 1 |
| Planchuelo-Gómez, Á | 1 |
| Martínez-Pías, E | 1 |
| Guerrero, ÁL | 1 |
| García-Azorín, D | 1 |
| Morris, B | 1 |
| Neher, J | 1 |
| Safranek, S | 1 |
| Loo, LS | 1 |
| Ailani, J | 1 |
| Schim, J | 1 |
| Baygani, S | 1 |
| Hundemer, HP | 1 |
| Port, M | 1 |
| Krege, JH | 1 |
| Stovner, LJ | 4 |
| Linde, M | 1 |
| Gravdahl, GB | 1 |
| Tronvik, E | 3 |
| Aamodt, AH | 1 |
| Sand, T | 2 |
| Hagen, K | 1 |
| Fehér, G | 1 |
| Pusch, G | 1 |
| Haaland, K | 1 |
| Gales, BJ | 1 |
| Bailey, EK | 1 |
| Reed, AN | 1 |
| Gales, MA | 1 |
| Silberstein, SD | 1 |
| Holland, S | 1 |
| Freitag, F | 1 |
| Dodick, DW | 1 |
| Argoff, C | 1 |
| Ashman, E | 1 |
| Akiyama, H | 1 |
| Hasegawa, Y | 1 |
| Helde, G | 1 |
| Bovim, G | 2 |
| Owada, K | 1 |
| Rapoport, AM | 1 |
| Bigal, ME | 1 |
| White, LR | 1 |
| Gladwin, AJ | 1 |
| Owen, K | 1 |
| Schrader, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study[NCT02439320] | Phase 3 | 2,231 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)[NCT02605174] | Phase 3 | 3,005 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| CandeSpartan Study Candesartan Spanish Response-prediction and Tolerability Study Observational Study on Response Predictors and Tolerability of Candesartan in Usual Clinical Practice[NCT04138316] | 85 participants (Actual) | Observational [Patient Registry] | 2020-01-02 | Completed | |||
| Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study[NCT00884663] | Phase 2/Phase 3 | 72 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Prophylactic Treatment of Episodic Cluster Headache With an Angiotensin II Receptor Blocker (Candesartan Cilexetil); a Randomized, Placebo Controlled Parallel Study[NCT00184587] | Phase 2 | 40 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section (NCT02439320)
Timeframe: Baseline up to 11 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| 100 mg Lasmiditan | 0 |
| 200 mg Lasmiditan | 2 |
| Placebo | 1 |
The percentage of participants without nausea. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 64.6 |
| 200 mg Lasmiditan | 64.1 |
| Placebo | 62.1 |
The percentage of participants without phonophobia. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 60.7 |
| 200 mg Lasmiditan | 58.7 |
| Placebo | 52.5 |
The percentage of participants without photophobia. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 53.9 |
| 200 mg Lasmiditan | 51.5 |
| Placebo | 38.1 |
The percentage of participants defined as mild, moderate, or severe headache pain becoming none. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 28.2 |
| 200 mg Lasmiditan | 32.2 |
| Placebo | 15.3 |
The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 40.9 |
| 200 mg Lasmiditan | 40.7 |
| Placebo | 29.5 |
The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none. (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 59.4 |
| 200 mg Lasmiditan | 59.5 |
| Placebo | 42.2 |
Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free). (NCT02439320)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 26.2 |
| 200 mg Lasmiditan | 20.7 |
| Placebo | 46.0 |
Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free). (NCT02439320)
Timeframe: Anytime 24-48 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 0 |
| 200 mg Lasmiditan | 0 |
| Placebo | 0 |
Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free). (NCT02439320)
Timeframe: Anytime between 2-24 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 8.9 |
| 200 mg Lasmiditan | 7.9 |
| Placebo | 11.7 |
Participants who received study drug and which became pain free at 2 hours post-dose and worsened again up to 48 hours post-dose. (NCT02439320)
Timeframe: From 2 hours post dose up to 48 hours
| Intervention | percentage of participants (Number) |
|---|---|
| 100 mg Lasmiditan | 8.4 |
| 200 mg Lasmiditan | 10.1 |
| Placebo | 5.1 |
Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study (NCT02439320)
Timeframe: 6 months prior to enrolling in study to end of study (Up to 11 Weeks) within 7 days of treating a single migraine attack
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 Months prior to enrolling | During time of study | |
| 100 mg Lasmiditan/100 mg Lasmiditan | 4.4 | 0.9 |
| 100 mg Lasmiditan/Placebo | 4.6 | 0.5 |
| 200 mg Lasmiditan/200 mg Lasmiditan | 3.0 | 0.2 |
| 200 mg Lasmiditan/Placebo | 2.5 | 0.5 |
| Placebo/Placebo | 2.8 | 0.6 |
The number of participants with headache recurrence (moderate or severe at baseline which became pain-free at 2 hours post dose and worsened again up to 48 hours post dose) (NCT02605174)
Timeframe: From 2 Hours Post Dose Up to 48 Hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Lasmiditan 50 mg | 38 |
| Lasmiditan 100 mg | 44 |
| Lasmiditan 200 mg | 52 |
| Placebo | 26 |
Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section (NCT02605174)
Timeframe: From Baseline Up to End of Study (Up to 11 Weeks)
| Intervention | participants (Number) |
|---|---|
| Lasmiditan 50 mg | 167 |
| Lasmiditan 100 mg | 230 |
| Lasmiditan 200 mg | 253 |
| Placebo | 75 |
The percentage of participants defined as mild, moderate, or severe headache pain becoming none. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 28.6 |
| Lasmiditan 100 mg | 31.4 |
| Lasmiditan 200 mg | 38.8 |
| Placebo | 21.3 |
The percentage of participant without nausea. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 68.7 |
| Lasmiditan 100 mg | 71.8 |
| Lasmiditan 200 mg | 70.4 |
| Placebo | 70.3 |
The percentage of participants who used rescue medication. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 31.9 |
| Lasmiditan 100 mg | 26.4 |
| Lasmiditan 200 mg | 18.9 |
| Placebo | 40.8 |
The percentage of participants who used rescue medication. (NCT02605174)
Timeframe: From 2 Hours Post Dose Up to 24 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 8.9 |
| Lasmiditan 100 mg | 6.3 |
| Lasmiditan 200 mg | 7.4 |
| Placebo | 8.7 |
The percentage of participants who used rescue medication. (NCT02605174)
Timeframe: From 24 Post Dose Up to 48 Hours
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 0.0 |
| Lasmiditan 100 mg | 0.0 |
| Lasmiditan 200 mg | 0.0 |
| Placebo | 0.0 |
The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 40.8 |
| Lasmiditan 100 mg | 44.2 |
| Lasmiditan 200 mg | 48.7 |
| Placebo | 33.5 |
The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 59.0 |
| Lasmiditan 100 mg | 64.8 |
| Lasmiditan 200 mg | 65.0 |
| Placebo | 47.7 |
The percentage of participants without phonophobia. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 61.2 |
| Lasmiditan 100 mg | 64.8 |
| Lasmiditan 200 mg | 65.3 |
| Placebo | 53.5 |
The percentage of participants without photophobia. (NCT02605174)
Timeframe: 2 hours post dose
| Intervention | percentage of participants (Number) |
|---|---|
| Lasmiditan 50 mg | 51.2 |
| Lasmiditan 100 mg | 56.4 |
| Lasmiditan 200 mg | 58.2 |
| Placebo | 43.2 |
Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study (NCT02605174)
Timeframe: 6 Months Prior to Enrolling in Study to End of Study (Up to 11 Weeks) Within 7 Days of Treating a Single Migraine Attack
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months prior to enrolling | During time of study | |
| Lasmiditan 100 mg/Lasmiditan 100 mg | 2.8 | 0.5 |
| Lasmiditan 100 mg/Placebo | 2.4 | 0 |
| Lasmiditan 200 mg/Lasmiditan 200 mg | 3.2 | 0.9 |
| Lasmiditan 200 mg/Placebo | 3.3 | 0.5 |
| Lasmiditan 50 mg/Lasmiditan 50 mg | 4.7 | 0.5 |
| Lasmiditan 50 mg/Placebo | 2.2 | 0 |
| Placebo/Placebo | 2.9 | 0.6 |
6 reviews available for candesartan and Abdominal Migraine
| Article | Year |
|---|---|
Clinical Inquiries. How effectively do ACE inhibitors and ARBs prevent migraines?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2018 |
[Role of antihypertensive drugs in the treatment of migraine].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2015 |
[Update on Current Care Guideline: Migraine].
Topics: Acetaminophen; Adrenergic beta-Antagonists; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, Opi | 2015 |
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2010 |
Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2012 |
Preventive migraine therapy: what is new.
Topics: Analgesics; Angiotensin-Converting Enzyme Inhibitors; Antidepressive Agents, Second-Generation; Anti | 2004 |
3 trials available for candesartan and Abdominal Migraine
| Article | Year |
|---|---|
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
Topics: Adult; Benzamides; Benzimidazoles; Biphenyl Compounds; Botulinum Toxins, Type A; Double-Blind Method | 2019 |
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
Topics: Adult; Benzamides; Benzimidazoles; Biphenyl Compounds; Botulinum Toxins, Type A; Double-Blind Method | 2019 |
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
Topics: Adult; Benzamides; Benzimidazoles; Biphenyl Compounds; Botulinum Toxins, Type A; Double-Blind Method | 2019 |
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
Topics: Adult; Benzamides; Benzimidazoles; Biphenyl Compounds; Botulinum Toxins, Type A; Double-Blind Method | 2019 |
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.
Topics: Adult; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2014 |
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.
Topics: Adult; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2014 |
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.
Topics: Adult; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2014 |
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.
Topics: Adult; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2014 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cross-O | 2003 |
8 other studies available for candesartan and Abdominal Migraine
| Article | Year |
|---|---|
Candesartan in migraine prevention: results from a retrospective real-world study.
Topics: Benzimidazoles; Biphenyl Compounds; Humans; London; Migraine Disorders; Retrospective Studies; Tetra | 2020 |
Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study.
Topics: Benzimidazoles; Biphenyl Compounds; Disease Management; Duration of Therapy; Female; Headache; Human | 2021 |
Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2010 |
Migraine treated using a prophylactic combination of candesartan and hydrochlorothiazide (ECARD Combination Tablets LD).
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Combinations; Edema; Female | 2013 |
BP drug for migraine prevention.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Human | 2003 |
Efficacy of candesartan in the treatment of migraine in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; Humans; | 2004 |
Migraine prophylaxis with drugs influencing the renin-angiotensin system.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2008 |